Transcript
Page 1: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Page 2: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy
Page 3: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Heart Failure Epidemiology (US Data)

Page 4: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

CHF Hospitalizations by Age, 2000 and 2010

Page 5: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Consequences of Heart Failure

Page 6: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Impact of Affordable Care Act on HF Readmission

Page 7: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Impact of Affordable Care Act on HF Readmission (cont)

Page 8: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

EVEREST Study

Page 9: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

EVEREST: NPs and Congestion Scores

Page 10: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Relationships Between Discharge BNP and Outcomes

Page 11: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Therapies With Effects on BNP Levels

Page 12: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

DOSE-AHF Study

Page 13: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Telemonitoring and Home-based Care

Page 14: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

The Importance of Serial NP Measurements for Prognostication

in Chronic HF

Page 15: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

PROTECT Study Primary End Point: Total Cardiovascular Events

Page 16: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

PROTECT Secondary End Points: HF Hospitalization and Rehospitalization

Page 17: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Guided Therapy Combined Analyses

Suggest Benefit, All-Cause Mortality

Page 18: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

The GUIDE-IT Trial

Page 19: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Home Testing

Page 20: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Abbreviations

Page 21: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Abbreviations (cont)

Page 22: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Abbreviations (cont)

Page 23: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

References

Page 24: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

References (cont)

Page 25: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

References (cont)

Page 26: Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

References (cont)


Recommended